A prospective phase II, randomized multi-center trial of a biomodulatory treatment with metronomic low-dose treosulfan, pioglitazone and clarithromycin versus docetaxel or docetaxel plus nintedanib in patients with non-small cell lung cancer (NSCLC) after platin failure (ModuLung)

Trial Profile

A prospective phase II, randomized multi-center trial of a biomodulatory treatment with metronomic low-dose treosulfan, pioglitazone and clarithromycin versus docetaxel or docetaxel plus nintedanib in patients with non-small cell lung cancer (NSCLC) after platin failure (ModuLung)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Apr 2017

At a glance

  • Drugs Pioglitazone (Primary) ; Treosulfan (Primary) ; Clarithromycin; Docetaxel
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms ModuLung
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 21 Jul 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top